NCT00624936 2017-08-22
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)